Content Loading...
Content Loading...
Product Images
Immunocytochemistry
PI3-Kinase, p110β staining of human kidney 2 mm array spot. Tissue pre-treated with Citrate pH 6.0 antigen-retrieval. Anti-P...
Confocal Immunocytochemistry Analysis
Hela cells were fixed, permeablized, and stained with anti- PI3K, p110β (Cy3, red), DAPI (blue, nuclei), an...
)
)
)
)
)
)
Anti-PI3 Kinase, p110β
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, Mk, Ca, M, R | WB, IP, IC, IH, ELISA | Rabbit | Affinity Purified | Polyclonal Antibody |
Description:
Anti-PI3 Kinase, p110β
Specificity:
Recognizes the internal domain of PI3 Kinase, p110β.
Molecular Weight:
110 kDa
Epitope:
Internal Domain
Immunogen:
KLH-conjugated synthetic linear peptide corresponding to the internal domain of PI3 Kinase, p110β.
Background Information:
PI3 Kinase (Phosphatidylinositol 3-Kinase) is responsible for phosphorylation of the 3 position of the inositol ring of PI(4,5)P2, to generate PI(3,4,5)P3, a potent second messenger required for survival, signaling, and insulin action. PI3 Kinase is a heterodimeric complex composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. Tyrosine phosphorylation of growth factor receptors creates docking sites for binding of p85 (through its SH2 domains) on the receptors; p85 brings with it p110, which is then proximal to its phospho-lipid substrate on the membrane. PI3 Kinase is also activated by Ras, and by the β:γ subunits of heterotrimeric G-proteins. PI3 Kinase is inhibitable by wortmannin, a useful tool for the study of the PI3 Kinase signaling pathway.
Species Reactivity:
- Human
- Monkey
- Canine
- Mouse
- Rat
Species Reactivity Note:
Human. Expected to react with Monkey, Dog, Rat and Mouse based on immunogen sequence homology.
Application Notes:
ELISA:
This antibody was tested and determined to work for ELISA at 0.5 ng/well.
This antibody was tested and determined to work for ELISA at 0.5 ng/well.
Control:
HEK-293 cell lysate.
Quality Assurance:
Evaluated by Western Blot on HEK-293 cell lysate.
Western Blot Analysis: 0.05 - 0.1 μg/mL of this antibody detected endogenous PI3 Kinase, p110β in lysate from HEK-293 cells.
Western Blot Analysis: 0.05 - 0.1 μg/mL of this antibody detected endogenous PI3 Kinase, p110β in lysate from HEK-293 cells.
Purification Method:
Affinity Purfied
Presentation:
Antigen affinity purified rabbit serum in 0.1M Tris-Glycine (pH7.4), 150mM NaCl, with 0.05% NaN3.
Storage Conditions:
Stable for 1 year at 2-8ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
UniProt Number:
Entrez Gene Number:
Gene Symbol:
- EC 2.7.1.153
- MGC142161
- MGC142163
- PI3K
- p110-alpha
Alternate Names:
- PI3-kinase p110 subunit alpha
- phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha
- PtdIns-3-kinase p110
- phosphatidylinositol 3-kinase, catalytic, alpha polypeptide
-
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit, alpha isoform - phosphoinositide-3-kinase, catalytic, alpha polypeptide
Usage Statement:
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Key Applications:
- Western Blotting
- Immunoprecipitation
- Immunocytochemistry
- Immunohistochemistry
- ELISA
UniProt Summary:
FUNCTION: Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2.
CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.
SUBUNIT STRUCTURE: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3 By similarity.
INVOLVEMENT IN DISEASE: Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].
Defects in PIK3CA are associated with breast cancer [MIM:114480].
Defects in PIK3CA are associated with epithelial ovarian cancer (EOC) [MIM:604370].
Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550]. Ref.14
PI3KCA mutations affecting exons 9 and 20 display gender- and tissue-specific patterns, thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore, sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles.
SEQUENCE SIMILARITIES: Belongs to the PI3/PI4-kinase family.
Contains 1 C2 domain.
Contains 1 PI3K/PI4K domain.
CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.
SUBUNIT STRUCTURE: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3 By similarity.
INVOLVEMENT IN DISEASE: Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].
Defects in PIK3CA are associated with breast cancer [MIM:114480].
Defects in PIK3CA are associated with epithelial ovarian cancer (EOC) [MIM:604370].
Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550]. Ref.14
PI3KCA mutations affecting exons 9 and 20 display gender- and tissue-specific patterns, thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore, sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles.
SEQUENCE SIMILARITIES: Belongs to the PI3/PI4-kinase family.
Contains 1 C2 domain.
Contains 1 PI3K/PI4K domain.
Qty/Pk:
100 μL
Format:
Affinity Purified
Host:
Rabbit
Product Name:
Anti-PI3 Kinase, p110β
Concentration:
0.5 mg/mL
Antibody Type:
Polyclonal Antibody